TABLE 1.

Primary and Secondary Outcomes

Primary Outcome
Cohort (n)Outcome (SD) on MetforminOutcome (SD) on Alternative RegimenP
Whole cohort (179)A1C: 7.7% (± 1.7%)Peak A1C within 1-year follow-up: 8.3% (± 2.0%)<0.001
Whole cohort (179)A1C: 7.7% (± 1.7%)A1C at 1-year follow-up: 7.6% (± 1.7%)0.45
Patients on oral agents only (48)A1C: 7.1% (± 1.3%)A1C (on alternative oral regimen) at 1-year follow-up: 7.1% (± 1.4%)0.96
Secondary Outcomes
Whole cohort (179)Weight: 98.1 kg (± 20.9 kg)Weight at 1-year follow-up: 101.9 kg (± 21 kg)<0.001
Patients on oral agents only (48)Weight: 93.7 kg (± 13.9 kg)Weight on alternative oral regimen at 1-year follow-up: 97.4 kg (± 15.6 kg)<0.001
Whole cohort (179)Monthly cost of metformin-containing therapy: $25.44 (± $26.49)Monthly cost of alternative therapy at 1-year follow-up: $46.11 (± $44.26)<0.001
Whole cohort (179)Hypoglycemia: n = 10 (5.6%) (5 did not experience hypoglycemia on alternative regimen)Hypoglycemia: n = 48 (26.8%)(5 also experienced hypoglycemia on metformin regimen)<0.001